The Impact of Sinopharm COVID-19 Vaccination on Male Fertility

Cairo University (CU)

Status: Unknown

Conditions: Male Infertility; Hypogonadism, Male

Treatments: Diagnostic Test: Semen analysis

Study type: Observational

Funder types: Other

Identifiers

NCT04946565

TBA

Details and patient eligibility

About

The investigators shall study the effect of Sinopharm vaccination on semen parameters and serum testosterone

Full description

The investigators shall compare semen parameter (sperm density, sperm motility, and percentage of abnormal sperm form) as well as morning serum testosterone before vaccination, and 3 months after the second dose of the vaccine.

Enrollment: 100 estimated patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Receiving Sinopharm COVID-19 vaccines Male age 18-50 years old

Exclusion criteria

• Adults unable to consent
• Men who have been receiving Testosterone replacement therapy or anabolic steroids within the last year
• Men with a history of male infertility
• Men with a genetic or other medical condition known to be associated with decreased semen parameters Positive COVID-19 PCR test within the 3 months

Trial design

100 participants in 1 patient group

Sinopharm vaccine group

Description:

Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.

Treatment:

Diagnostic Test: Semen analysis